Methods of treating hypoxia-associated optical conditions with cartilage oligo matrix protein-angiopoietin 1 (comp-ang1)
AssigneeUniversity of Utah Research Foundation
InventorsBalamurali K. Ambati, Hironori Uehara, Judd Hoon
Life of this patent
Estimating the term…
Abstract
Methods, compositions, and systems for treating ischemia-associated and other ocular conditions using cartilage oligo matrix protein-Angiopoietin 1 (COMP-Ang1) are disclosed and described.
Claims49
A method of treating a disease or disorder of the eye, comprising administering a therapeutically effective amount of a cartilage oligo matrix protein-Angiopoietin 1 (COMP-Ang1) agent to an eye of a subject during a treatment period.
A therapeutic construct for treating an ocular disease or disorder, comprising:
- a vector backbone contained in a viral particle, the vector backbone including a sequence that is at least 80% homologous with SEQ ID 001.
A composition for treating a disease or disorder of the eye, comprising:
- a therapeutically effective amount of a COMP-Ang1 agent;
- and
- a pharmaceutically acceptable carrier.
A system for treating a disease or disorder in an eye of a subject, comprising:
- a composition, comprising:
- a therapeutically effective amount of a COMP-Ang1 agent;
- and
- a pharmaceutically acceptable carrier;
- and
- a container configured to house and store the composition prior to administration thereof to a subject.
Dependencies are inferred from the claim text.